Goserelin
A synthetic gonadotropin-releasing hormone agonist used to reduce testosterone or estrogen levels as a treatment for prostate cancer, breast cancer, endometriosis, and uterine fibroids by initially stimulating and then suppressing sex hormone production. Regular monthly or three-monthly subcutaneous implants maintain hormone suppression. It is also used to protect ovarian function during chemotherapy.
Khối lượng phân tử
1269,4000 g/mol
LogP
-1,50
TPSA
496,00 Ų
Lipinski RO5
Không đạt
Lĩnh vực điều trị
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
InChI
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
Molecular Formula
C59H84N18O14
HBD / HBA
17 / 16
Liên kết có thể quay
32
Nguyên tử nặng
91
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A synthetic gonadotropin-releasing hormone agonist used to reduce testosterone or estrogen levels as a treatment for prostate cancer, breast cancer, endometriosis, and uterine fibroids by initially stimulating and then suppressing sex hormone production. Regular monthly or three-monthly subcutaneous implants maintain hormone suppression. It is also used to protect ovarian function during chemotherapy.
Yes, Goserelin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201247. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311128. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="goserelin"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/goserelin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/goserelin/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/goserelin/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="goserelin"></drugfyi-drug>